Dermisonics

Dermisonics was a development-stage biopharmaceutical company focused on the development and commercialization of ultrasonic transdermal drug-delivery technologies. The company's primary technology, the U-Strip, was an active transdermal patch designed to facilitate the needle-free delivery of large molecular structure drugs, such as insulin, into the bloodstream using ultrasonic frequencies. Founded in 2000 and formerly known as Second Stage Ventures, the company aimed to provide non-invasive alternatives to traditional injections for various therapeutic agents. However, the company has become largely inactive, with its technology and intellectual property often associated with successor entities like Transdermal Specialties Global.